Jul 2026· Expert Opinion on Pharmacotherapy· Vol 27, pp. 1293 - 1308· 0 citations· 84 references
Medicine
TL;DR
New therapies, including dual AT1/endothelin-A antagonism and podocyte-targeted approaches (apecotrep), show promising proteinuria reductions but have not yet demonstrated clear benefits on hard renal outcomes, while biomarker-driven strategies may enable more tailored treatment, although their clinical impact remains to be established.
Abstract
ABSTRACT Introduction FSGS is a histological convergence point for biologically distinct conditions: primary immune-mediated, genetic, and secondary adaptive forms, each with its own pharmacological logic. ACE inhibitors and angiotensin receptor blockers have anchored its management for three decades on evidence drawn predominantly from non-FSGS populations. Areas covered Experimental and clinical literature from PubMed/MEDLINE, Embase, and Web of Science through 30 January 2026, covering angiotensin II–mediated podocyte injury, RAAS pharmacology across FSGS subtypes, and emerging strategies that extend or layer upon the RAAS backbone, including dual AT1/endothelin-A blockade, SGLT2 inhibition, and mineralocorticoid receptor antagonism, with additional podocyte-targeted and genotype-guided approaches. Expert opinion The clinical benefit of RAAS blockade appears to vary across FSGS subtypes. It likely targets a key pathogenic mechanism in secondary adaptive forms, while serving mainly as supportive antiproteinuric therapy in immune-mediated and genetic disease. Nonetheless, it remains a cornerstone of care. Emerging therapies, including dual AT1/endothelin-A antagonism (sparsentan) and podocyte-targeted approaches (apecotrep), show promising proteinuria reductions but have not yet demonstrated clear benefits on hard renal outcomes. Biomarker-driven strategies (e.g. anti-nephrin antibodies, APOL1 genotyping) may enable more tailored treatment, although their clinical impact remains to be established.
ABSTRACT Introduction Focal segmental glomerulosclerosis (FSGS) represents a histopathologic pattern of glomerular injury rather than a single disease entity. In FSGS, prognosis varies substantially according to the degree of proteinuria. Despite optimized supportive therapy and, in presumed primary FSGS, immunosuppres...
Cristián Juanet, María José Soler, L. Zand et al.· Expert Opinion on Pharmacoth...· 0 citations
Renin–angiotensin system inhibitors, sodium–glucose cotransporter-2 inhibitors, finerenone, and glucagon-like peptide-1 receptor agonists improve cardiorenal outcomes and have plausible anti-inflammatory actions, although inflammatory mediation remains unproven.
Aris Tsalouchos, P. Dattolo· Journal of Clinical Medicine· 0 citations
Nephrolithiasis is a prevalent, highly recurrent urological disorder affecting 1%–15% of the global population, with 5-year recurrence rates reaching up to 50%. While surgical interventions achieve acute stone clearance, they do not resolve underlying metabolic derangements, crystal-induced tubular injury, or chronic i...
Xu-Ming Zhang, Chao-Yue Ji, Wei-Guo Hu· Frontiers in Pharmacology· 0 citations
INTRODUCTION AND OBJECTIVES
Portal hypertension has a limited pharmacological armamentarium despite decades of preclinical therapeutic research. We mapped the experimental architecture of this literature, independently of reported treatment efficacy.
MATERIALS AND METHODS
PubMed/MEDLINE was searched from inception to...
Sergi Guixé-Muntet, Anabel Fernández-Iglesias, Verónica Arreaza-Gil et al.· Annals of Hepatology· 0 citations
The therapeutic landscape of cardiorenal syndrome (CRS) has evolved significantly, transitioning from historical cornerstones like angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) to modern neurohormonal modulation with angiotensin receptor–neprilysin inhibitors (ARNIs). This seco...
A. Mauriello, V. Cetoretta, Carmen Del Giudice et al.· Biomedicines· 0 citations